United Therapeutics Corporation (UTHR)

NMS – Real vaqt narxi. Valyuta: USD

581.74

+11.86 (2.08%)

Yopilishda: May 12, 2026, 4:00 PM EDT

580.00

-1.74 (-0.30%)

Bozor oldidan: May 13, 2026, 9:02 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

United Therapeutics Corporation (UTHR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

United Therapeutics Corporation (UTHR)

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Videolar

No Data

Press-relizlar

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

Search stocks

United Therapeutics Corporation (UTHR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

United Therapeutics Corporation (UTHR)

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Videolar

No Data

Press-relizlar

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026